KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBITDA Margin (2018 - 2026)

Castle Biosciences' EBITDA Margin history spans 8 years, with the latest figure at 4.4% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 909.0% to 4.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.44%, a 1505.0% decrease, with the full-year FY2025 number at 12.44%, down 1505.0% from a year prior.
  • EBITDA Margin hit 4.4% in Q4 2025 for Castle Biosciences, up from 8.19% in the prior quarter.
  • Over the last five years, EBITDA Margin for CSTL hit a ceiling of 5.92% in Q3 2024 and a floor of 91.7% in Q1 2022.
  • Historically, EBITDA Margin has averaged 26.46% across 5 years, with a median of 17.22% in 2023.
  • Biggest five-year swings in EBITDA Margin: plummeted -7294bps in 2022 and later skyrocketed 6749bps in 2024.
  • Tracing CSTL's EBITDA Margin over 5 years: stood at 25.68% in 2021, then crashed by -132bps to 59.55% in 2022, then soared by 86bps to 8.56% in 2023, then skyrocketed by 155bps to 4.69% in 2024, then tumbled by -194bps to 4.4% in 2025.
  • Business Quant data shows EBITDA Margin for CSTL at 4.4% in Q4 2025, 8.19% in Q3 2025, and 4.93% in Q2 2025.